Biosyntia secures Series B funding for “world’s first” natural B-vitamin production

04 Oct 2022 --- Biosyntia has closed a Series B funding round at €17.5 million (US$ 17.3 million) to scale the production of the “world’s first natural and sustainably produced biotin, vitamin B7, an essential B-vitamin used in a range of applications.”

The investment will also enable Biosyntia to increase the production of environmentally sustainable active ingredients for personal care and human and animal nutrition.

The Danish biotech company will further commercialize additional active ingredients and advance its technology platform around vitamins and other health nutraceuticals to become a multi-ingredient manufacturer.

Investment players
The European Circular Bioeconomy Fund led the round alongside Novo Holdings and Sofinnova Partners, who invested in a series B funding round in June this year. Praesidium and Vækstfonden now join the investors in the follow-on closing.

Biosyntia aims to become a leading B2B ingredient manufacturer, selling its ingredients worldwide to a range of customers within consumer products.

Danish biotech company, Biosyntia, has closed a follow-on investment to their Series B totaling US$17.3M.All five investors are seasoned in biotechnology with a significant portfolio of technology investments. This is projected to enable a “green transition in manufacturing.”

Market placement
Biosyntia specializes in fermentation processes for vitamins and other active ingredients. The company’s production process offers an alternative to today’s production processes, mainly based in Asia.

“With its proprietary fermentation technology, Biosyntia can produce active ingredients as a sustainable, natural and high-quality alternative to current production methods. Specifically, Biosyntia’s technology offers an alternative to chemical-based production, resulting in less chemical waste and air pollution,” the company states.

Furthermore, Biosyntia offers an alternative production method to plant active materials, which requires significantly less land and fewer organic solvents in production.

Biotech developments
Earlier this year, Biosyntia partnered with Wacker Chemie, a German polymer supplier, to develop a large-scale production process for fermentation-based biotin based on Biosyntia’s microbial technology.

The two companies aim for the material to be available “for the full range of relevant applications as a sustainable, non-chemical, European-sourced alternative.” It is currently only produced synthetically from petrochemicals.

Fermentation has expanded from an ancient method of food preservation to offering the beauty and personal care space cleaner, sustainable and affordable ingredients. PersonalCareInsights previously highlighted the production method used by industry experts specializing in fermentation and biotechnology.

Edited by Radhika Sikaria

To contact our editorial team please email us at editorial@cnsmedia.com